|
||||||||
Company Profile | ||||||||
Chairman | CEO | Spokesperson | Tel | Address | Date of Listing (Regular) | |||
---|---|---|---|---|---|---|---|---|
Cheng-Chung Liu | De-Yu Zhong | Yu Yen Fu | 04-24639869 | No.19,Keyuan 2nd Road,Central Taiwan Science Park,Taichung City,Taiwan R.O.C | 2014/08/14 | |||
Industry | Main Business | |||||||
Agricultural Technology Industry | GeneReach Biotechnology Corporation is a worldwide biotechnology company dedicated to bringing the innovation to global health management. By developing, manufacturing and marketing products for applied nucleic acid detection technology, we offer disease detection platforms, including equipments and reagents, to multiple industries. Our products are currently in aquaculture, agriculture and companion animal industries. In the near future, we will launch the diagnostic kits for livestock and human. Since its commencement, GeneReach Biotechnology Corporation has set the goal to become the best company in molecular diagnosis industry. Specifically, our mission is to provide the best and affordable molecular diagnostics to the point of care market, and our vision is enriching your life. We believe our platform technologies will revolutionize health management industry. Through our platform technologies, we will help more lives and guarantee satisfied customers. |
Market Information ( 2024/04/24 ) | |||||||||||
Shr. Vol. | Highest | Lowest | Closed | Change | Transaction | TurnOver(%) | long margin balance (1,000shr.) |
Short margin balance (1,000shr.) |
|||
---|---|---|---|---|---|---|---|---|---|---|---|
136.674 | 31.40 | 30.60 | 31.25 | 0.60 | 152 | .00 | 1,690 | 1 | |||
Trading method | Fun purchase price or securities pneeded on T day |
Announcement of Irregularity (2024/04/25) |
TPEx measures adopted (2024/04/25) |
With warrants | Can be shorted or margined? | Detail | |||||
Normal | N | N | N | N | Y | Today | History |
Financial Reports | |||||
---|---|---|---|---|---|
Cash Flows | Items | ||||
Amount (NT$ thousand) |
|||||
Cash flows from operating activities | |||||
Cash flows from investing activities | |||||
Cash flows from financing activities | |||||
Balance Sheets |
Current assets | ||||
Non-current assets | |||||
Total assets | |||||
Current liabilities | |||||
Non-current liabilities | |||||
Total liabilities | |||||
Share capital | |||||
Capital surplus | |||||
Retained earnings | |||||
Other equity interest | |||||
Treasury shares | |||||
Total equity attributable to owners of parent | |||||
Non-controlling interests | |||||
Total equity | |||||
Book Value per share(NT$) | |||||
Comprehensive Income | Operating revenue | ||||
Operating costs | |||||
Gross profit from operations | |||||
Operating expenses | |||||
Net other income (expenses) | |||||
Net operating income | |||||
Non-operating income and expenses | |||||
Profit before tax | |||||
Tax expense | |||||
Profit from continuing operations | |||||
Profit from discontinued operations | |||||
Profit | |||||
Other comprehensive income | |||||
Comprehensive income | |||||
Basic earnings per share |
Auditor's report on latest financial statements: auditor's report: |
More detail:MOPS。 |
Foreign issuers’ information is disclosed in consolidated statements. |